The Asston Pharmaceuticals Limited IPO is opening on 9 July 2025 and will close on 11 July 2025. This is an SME IPO raising ₹27.56 crore from a fresh issue of 22.41 lakh equity shares.
The Asston Pharmaceuticals IPO allotment date will be decided on Monday, 14 July 2025. Asston Pharmaceuticals shares will be tentatively listed on BSE SME on Wednesday, 16 July 2025.
The Asston Pharmaceuticals price band has been between ₹115 and ₹123 per share. The lot size decided for the IPO is 1000 shares. The retail investors have to subscribe to at least 2 lots, which makes the minimum investment as ₹230000. For HNIs, it is 3 lots amounting to ₹369000.
Here Are the Quick Steps to Apply for the Asston Pharmaceuticals IPO with the Best SME IPO App!
Asston Pharmaceuticals BSE SME IPO Details
| Detail | Information |
| IPO Opening Date | July 9, 2025 |
| IPO Closing Date | July 11, 2025 |
| Tentative IPO Listing Date | July 16, 2025 |
| Face Value | ₹10 per share |
| Price Range | ₹115 to ₹123 per share |
| Lot Size | 1000 shares |
| Total Issue Size | 2241000 Shares (₹27.56 Cr.) |
| Reserved for Market Makers | 113000 Shares (₹1.39 Cr.) |
| Net offered to the Public | 2128000 Shares (₹26.17 Cr.) |
| Fresh Issue (Ex Market Maker) | 2128000 Shares (₹26.17 Cr.) |
| IPO Segment | Book Building Issue |
| Listing At | BSE SME |
| Shareholding Pre-Issue | 6271360 shares |
| Shareholding post-issue | 8512360 shares |
Asston Pharmaceuticals Limited | Company Overview
Asston Pharmaceuticals Limited was started in 2019 to engage in the pharma business, where it specializes in healthcare products export to global clients. From tablets to syrups, vitamins, to antibiotics, it manufactures and directly sells to clients.
It also works on a Contract Manufacturing or loan license basis that works on a principal-to-principal basis for different marketers. FDA has certified Asston Pharmaceuticals at both the Central and State levels. It is also accredited by NQA (Nuclear Quality Assurance) and it also complies with the quality management system (QMS) standards to ensure that all the products offered are of high quality and standard.
Some of the products which Asston specializes in include –
- Diclofenac 100 mg, which is used for nonsteroidal anti-inflammatory drugs
- Ferrovit Syrups for minerals and vitamin deficiency patients
- Albendazole USP 400 mg, which is an anti-worm drug
- Ibuprofen and Paracetamol, the two most common over-the-counter drugs used in pain relief and fever.
Asston Pharmaceuticals Limited IPO | Key Details
- Asston Pharmaceuticals IPO Opening Date: July 9, 2025,
- Asston Pharmaceuticals IPO Closing Date: July 11, 2025.
- Allotment Date: July 14, 2025
- Price Band: ₹115 to ₹123 per share
- Lot Size: 1000 shares
- Refunds Initiated: July 15, 2025
- Shares Credited to Demat: July 15, 2025
- Listing Date: July 16, 2025
Asston Pharmaceuticals Ltd: Financial Overview
Asston Pharmaceuticals Limited’s profits surged by a massive 218%, from a 61.7% jump in revenue during FY25.
Here is a snapshot of the financials –
Amounts in ₹ Crore
| Financial Information | 31-Mar-25 | 31-Mar-24 | Change | Change (%) |
| Assets | 28.12 | 20.26 | 7.86 | 38.79565647 |
| Revenue | 25.61 | 15.84 | 9.77 | 61.67929293 |
| Profit After Tax | 4.33 | 1.36 | 2.97 | 218.3823529 |
| EBITDA | 6.16 | 2.55 | 3.61 | 141.5686275 |
| Net Worth | 10.72 | 6.39 | 4.33 | 67.76212833 |
| Reserves and Surplus | 4.45 | 5.61 | -1.16 | -20.6773619 |
| Total Borrowing | 7.26 | 6.82 | 0.44 | 6.451612903 |
Asston Pharmaceuticals Ltd IPO | FAQs
Asston Pharmaceuticals Ltd manufactures and supplies a wide range of pharmaceutical drugs and products across the globe.
The tentative IPO listing date of Asston Pharmaceuticals has been fixed as Wednesday, 16 July 2025.
The bidding date for the Asston Pharmaceuticals IPO is July 9, 2025, and it will continue until July 11, 2025.
The minimum IPO lot size for Asston Pharmaceuticals is 1000 shares.
The IPO allotment is expected to be finalized on Monday, July 14, 2025.
The IPO face value is set at ₹10 per share.
______________________________________________________________________________________
Disclaimer: Investments in the securities market are subject to market risks; read all the related documents carefully before investing.